🗞Medical articles
Topic: Epilepsy drug shows promise for treating obstructive sleep apnea
In a double-blind, randomized,
placebo-controlled trial involving patients with obstructive sleep apnea (OSA), the carbonic anhydrase inhibitor sulthiame (STM; currently used as anticonvulsant outside of the U.S.) improved sleep quality, hypoxia, and daytime sleepiness while also reducing sleep disordered breathing. The findings were presented at the recent European Respiratory Society Congress in Vienna, Austria.
@HakimApps_Guideline
#Articles #MedicalNews
https://www.epocrates.com/online/contextuallink/article/ers-2024-epilepsy-drug-shows-promise-for-treating-obstructive-sleep-apnea?utm_source=share&utm_medium=member_android
Source: European Respiratory Society 2024
Topic: Epilepsy drug shows promise for treating obstructive sleep apnea
In a double-blind, randomized,
placebo-controlled trial involving patients with obstructive sleep apnea (OSA), the carbonic anhydrase inhibitor sulthiame (STM; currently used as anticonvulsant outside of the U.S.) improved sleep quality, hypoxia, and daytime sleepiness while also reducing sleep disordered breathing. The findings were presented at the recent European Respiratory Society Congress in Vienna, Austria.
@HakimApps_Guideline
#Articles #MedicalNews
https://www.epocrates.com/online/contextuallink/article/ers-2024-epilepsy-drug-shows-promise-for-treating-obstructive-sleep-apnea?utm_source=share&utm_medium=member_android